Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VCB-1301
- Development stage
- Preclinical
- Lead developer
- Vaxcell-Bio Therapeutics
- Modality
- Small Molecules
01
Overview
VCB-1301 is an investigational small molecule targeted therapy developed by the South Korean biotechnology company Vaxcell Bio. Currently in the preclinical stage of development, the agent is being evaluated for its potential to treat various solid tumors. Unlike Vaxcell Bio's primary portfolio of cell-based immunotherapies (such as NK cell and CAR-T therapies), VCB-1301 represents a traditional pharmacological approach to oncology, aiming to disrupt specific molecular drivers of cancer cell growth and survival. While the specific molecular target has not been publicly disclosed in the company's high-level pipeline overview, the drug is designed to selectively interfere with pathways essential for tumor progression.
Beyond the preview
Go deeper on VCB-1301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VCB-1301.